Published in Cell Death Dis on October 24, 2013
Reactive oxygen species and autophagy associated apoptosis and limitation of clonogenic survival induced by zoledronic acid in salivary adenoid cystic carcinoma cell line SACC-83. PLoS One (2014) 0.91
The potential of panobinostat as a treatment option in patients with relapsed and refractory multiple myeloma. Ther Adv Hematol (2014) 0.88
Zoledronate blocks geranylgeranylation not farnesylation to suppress human osteosarcoma U2OS cells metastasis by EMT via Rho A activation and FAK-inhibited JNK and p38 pathways. Oncotarget (2016) 0.81
Valproic acid potentiates the anticancer activity of capecitabine in vitro and in vivo in breast cancer models via induction of thymidine phosphorylase expression. Oncotarget (2016) 0.78
Synergistic antitumor activity of histone deacetylase inhibitors and anti-ErbB3 antibody in NSCLC primary cultures via modulation of ErbB receptors expression. Oncotarget (2016) 0.78
Oxidative stress and proteasome inhibitors in multiple myeloma. Pharmacol Res (2016) 0.77
Molecular mechanisms of suberoylanilide hydroxamic acid in the inhibition of TGF-β1-mediated canine corneal fibrosis. Vet Ophthalmol (2015) 0.76
Dual roles of extracellular signal-regulated kinase (ERK) in quinoline compound BPIQ-induced apoptosis and anti-migration of human non-small cell lung cancer cells. Cancer Cell Int (2017) 0.75
Reactive oxygen species are required for zoledronic acid-induced apoptosis in osteoclast precursors and mature osteoclast-like cells. Sci Rep (2017) 0.75
Oxidative Stress Gene Expression Profile Correlates with Cancer Patient Poor Prognosis: Identification of Crucial Pathways Might Select Novel Therapeutic Approaches. Oxid Med Cell Longev (2017) 0.75
Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med (2009) 13.74
Signal integration by JNK and p38 MAPK pathways in cancer development. Nat Rev Cancer (2009) 9.33
Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst (2004) 5.87
First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial. Lancet (2010) 5.04
p38 MAP-kinases pathway regulation, function and role in human diseases. Biochim Biophys Acta (2007) 4.80
Breast-cancer adjuvant therapy with zoledronic acid. N Engl J Med (2011) 4.51
Role of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitors. Proc Natl Acad Sci U S A (2005) 3.20
The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species. Proc Natl Acad Sci U S A (2001) 2.65
Molecular pathogenesis of multiple myeloma and its premalignant precursor. J Clin Invest (2012) 2.24
Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results. Ann Oncol (2012) 2.16
Novel therapies for metastatic castrate-resistant prostate cancer. J Natl Cancer Inst (2011) 1.98
Biochemical and molecular mechanisms of action of bisphosphonates. Bone (2010) 1.92
Antitumor effects of doxorubicin followed by zoledronic acid in a mouse model of breast cancer. J Natl Cancer Inst (2008) 1.87
Effects of bone-targeted agents on cancer progression and mortality. J Natl Cancer Inst (2012) 1.69
Farnesol and geranylgeraniol prevent activation of caspases by aminobisphosphonates: biochemical evidence for two distinct pharmacological classes of bisphosphonate drugs. Mol Pharmacol (1999) 1.48
The 39th David A. Karnofsky Lecture: bench-to-bedside translation of targeted therapies in multiple myeloma. J Clin Oncol (2012) 1.46
HDAC inhibitor vorinostat enhances the antitumor effect of gefitinib in squamous cell carcinoma of head and neck by modulating ErbB receptor expression and reverting EMT. J Cell Physiol (2011) 1.37
A phase I study of oral panobinostat alone and in combination with docetaxel in patients with castration-resistant prostate cancer. Cancer Chemother Pharmacol (2010) 1.32
Combination strategy targeting the hypoxia inducible factor-1 alpha with mammalian target of rapamycin and histone deacetylase inhibitors. Clin Cancer Res (2008) 1.31
The DnaJ-related factor Mrj interacts with nuclear factor of activated T cells c3 and mediates transcriptional repression through class II histone deacetylase recruitment. Mol Cell Biol (2005) 1.25
Emerging anti-cancer molecular mechanisms of aminobisphosphonates. Endocr Relat Cancer (2006) 1.25
The pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with varying degrees of renal function. J Clin Pharmacol (2003) 1.16
HMG-CoA reductase inhibitors induce apoptosis of lymphoma cells by promoting ROS generation and regulating Akt, Erk and p38 signals via suppression of mevalonate pathway. Cell Death Dis (2013) 1.12
The third-generation bisphosphonate zoledronate synergistically augments the anti-Ph+ leukemia activity of imatinib mesylate. Blood (2003) 1.11
Synergistic antitumor effect between vorinostat and topotecan in small cell lung cancer cells is mediated by generation of reactive oxygen species and DNA damage-induced apoptosis. Mol Cancer Ther (2009) 1.10
Pathways of chemotherapy resistance in castration-resistant prostate cancer. Endocr Relat Cancer (2011) 1.07
R115777 (Zarnestra)/Zoledronic acid (Zometa) cooperation on inhibition of prostate cancer proliferation is paralleled by Erk/Akt inactivation and reduced Bcl-2 and bad phosphorylation. J Cell Physiol (2007) 1.02
Zoledronic acid significantly enhances radiation‑induced apoptosis against human fibrosarcoma cells by inhibiting radioadaptive signaling. Int J Oncol (2012) 0.99
Statins and prostate cancer: role of cholesterol inhibition vs. prevention of small GTP-binding proteins. Am J Cancer Res (2011) 0.97
Modulation of thymidilate synthase and p53 expression by HDAC inhibitor vorinostat resulted in synergistic antitumor effect in combination with 5FU or raltitrexed. Cancer Biol Ther (2009) 0.97
Acquired resistance to zoledronic acid and the parallel acquisition of an aggressive phenotype are mediated by p38-MAP kinase activation in prostate cancer cells. Cell Death Dis (2013) 0.95
Geraniol attenuates 12-O-tetradecanoylphorbol-13-acetate (TPA)-induced oxidative stress and inflammation in mouse skin: possible role of p38 MAP Kinase and NF-κB. Exp Mol Pathol (2013) 0.94
Preclinical data and early clinical experience supporting the use of histone deacetylase inhibitors in multiple myeloma. Leuk Res (2013) 0.94
Vorinostat synergises with capecitabine through upregulation of thymidine phosphorylase. Br J Cancer (2010) 0.94
Synergistic activity of the histone deacetylase inhibitor suberoylanilide hydroxamic acid and the bisphosphonate zoledronic acid against prostate cancer cells in vitro. Mol Cancer Ther (2007) 0.91
Efficacy of a nitrogen-containing bisphosphonate, minodronate, in conjunction with a p38 mitogen activated protein kinase inhibitor or doxorubicin against malignant bone tumor cells. Cancer Chemother Pharmacol (2007) 0.91
Inhibition of heat-shock protein 27 expression eliminates drug resistance of osteosarcoma to zoledronic acid. Anticancer Res (2010) 0.87
Inhibition of the mevalonate pathway and activation of p38 MAP kinase are independently regulated by nitrogen-containing bisphosphonates in breast cancer cells. Eur J Pharmacol (2007) 0.87
Zoledronic acid cooperates with a cyclooxygenase-2 inhibitor and gefitinib in inhibiting breast and prostate cancer. Endocr Relat Cancer (2005) 0.86
EPN: a novel epithelial cell line derived from human prostate tissue. In Vitro Cell Dev Biol Anim (2002) 0.82
Proteomic analysis identifies differentially expressed proteins after HDAC vorinostat and EGFR inhibitor gefitinib treatments in Hep-2 cancer cells. Proteomics (2011) 0.80
Pharmacokinetic evaluation of zoledronic acid. Expert Opin Drug Metab Toxicol (2011) 0.80
Geranylgeranylated proteins are involved in the regulation of myeloma cell growth. Clin Cancer Res (2005) 0.79
Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet (1992) 5.36
The effects of frequent nocturnal home hemodialysis: the Frequent Hemodialysis Network Nocturnal Trial. Kidney Int (2011) 4.27
KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer. Br J Cancer (2009) 3.73
A comparison of noninvasive positive-pressure ventilation and conventional mechanical ventilation in patients with acute respiratory failure. N Engl J Med (1998) 3.35
Structural basis of end-stage failure in ischemic cardiomyopathy in humans. Circulation (1994) 3.24
Noninvasive ventilation for treatment of acute respiratory failure in patients undergoing solid organ transplantation: a randomized trial. JAMA (2000) 3.20
The C. elegans unc-104 gene encodes a putative kinesin heavy chain-like protein. Neuron (1991) 2.52
Noninvasive vs. conventional mechanical ventilation in patients with chronic obstructive pulmonary disease after failure of medical treatment in the ward: a randomized trial. Intensive Care Med (2002) 2.37
Identification of a second human nm23 gene, nm23-H2. Cancer Res (1991) 2.31
Prospective multicenter study on epidemiology of acute kidney injury in the ICU: a critical care nephrology Italian collaborative effort (NEFROINT). Minerva Anestesiol (2011) 2.13
A c-erb-A binding site in rat growth hormone gene mediates trans-activation by thyroid hormone. Nature (1987) 2.11
Management of cancer pain: ESMO Clinical Practice Guidelines. Ann Oncol (2012) 2.07
Potential utility of early metabolic response by 18F-2-fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography in a selected group of breast cancer patients receiving preoperative chemotherapy. Eur J Cancer (2013) 2.01
Antigen retrieval techniques in immunohistochemistry: comparison of different methods. J Pathol (1997) 2.01
Subclinical Cushing's syndrome in patients with adrenal incidentaloma: clinical and biochemical features. J Clin Endocrinol Metab (2000) 1.99
Familial papillary thyroid microcarcinoma: a new clinical entity. Lancet (1999) 1.98
Effects of amlodipine and valsartan on oxidative stress and plasma methylarginines in end-stage renal disease patients on hemodialysis. Kidney Int (2006) 1.94
Identification of a calcium channel modulator using a high throughput yeast two-hybrid screen. Nat Biotechnol (1998) 1.92
The basal-like breast carcinoma phenotype is regulated by SLUG gene expression. J Pathol (2008) 1.83
Amphipols from A to Z. Annu Rev Biophys (2011) 1.75
Effects of a nitric oxide synthase inhibitor in humans with septic shock. Cardiovasc Res (1994) 1.74
A mouse model for hereditary thyroid dysgenesis and cleft palate. Nat Genet (1998) 1.74
Association of nm23-H1 allelic deletions with distant metastases in colorectal carcinoma. Lancet (1991) 1.74
The cellular basis of dilated cardiomyopathy in humans. J Mol Cell Cardiol (1995) 1.64
Idiosyncratic reaction after oxaliplatin infusion. Ann Oncol (2001) 1.63
Genetic modulation of the Let-7 microRNA binding to KRAS 3'-untranslated region and survival of metastatic colorectal cancer patients treated with salvage cetuximab-irinotecan. Pharmacogenomics J (2010) 1.63
Discrete cis-active genomic sequences dictate the pituitary cell type-specific expression of rat prolactin and growth hormone genes. Nature (1986) 1.62
Contagious yawning in gelada baboons as a possible expression of empathy. Proc Natl Acad Sci U S A (2009) 1.61
Evidence for the release of endogenous substance P from intestinal nerves. Naunyn Schmiedebergs Arch Pharmacol (1979) 1.61
Bone metastases in breast cancer: higher prevalence of osteosclerotic lesions. Radiol Med (2007) 1.58
Percutaneous computed tomography-guided ethanol injection in aldosterone-producing adrenocortical adenoma. Eur J Endocrinol (1995) 1.56
An ankyrin-related gene (unc-44) is necessary for proper axonal guidance in Caenorhabditis elegans. J Cell Biol (1995) 1.55
Efficacy of tissue plasminogen activator administration on patency of hemodialysis access catheters. Am J Kidney Dis (2000) 1.55
BAG3 protein controls B-chronic lymphocytic leukaemia cell apoptosis. Cell Death Differ (2003) 1.53
Dopamine D1 and adenosine A1 receptors form functionally interacting heteromeric complexes. Proc Natl Acad Sci U S A (2000) 1.53
Endogenous dimethylarginine as an inhibitor of nitric oxide synthesis. J Cardiovasc Pharmacol (1992) 1.51
Elution of fibronectin proteolytic fragments from a hydroxyapatite chromatography column. A simple procedure for the purification of fibronectin domains. Eur J Biochem (1985) 1.51
IFN-gamma up-regulates the A2B adenosine receptor expression in macrophages: a mechanism of macrophage deactivation. J Immunol (1999) 1.51
Outcome of antenatally diagnosed intracranial hemorrhage: case series and review of the literature. Ultrasound Obstet Gynecol (2003) 1.48
Receptor heteromerization in adenosine A2A receptor signaling: relevance for striatal function and Parkinson's disease. Neurology (2003) 1.48
CD26, adenosine deaminase, and adenosine receptors mediate costimulatory signals in the immunological synapse. Proc Natl Acad Sci U S A (2005) 1.45
Transcranial Doppler for brain death after decompressive craniectomy: persistence of cerebral blood flow with flat EEG. Intensive Care Med (2010) 1.44
The translation elongation factor 1A in tumorigenesis, signal transduction and apoptosis: review article. Amino Acids (2004) 1.44
An update on adenosine A2A-dopamine D2 receptor interactions: implications for the function of G protein-coupled receptors. Curr Pharm Des (2008) 1.43
Onychoblastoma (hamartoma of the nail unit): a new entity? Br J Dermatol (2005) 1.43
Effects of ligand-mimetic peptides Arg-Gly-Asp-X (X = Phe, Trp, Ser) on alphaIIbbeta3 integrin conformation and oligomerization. Biochemistry (1999) 1.43
Gastrointestinal autonomic nerve tumor of the jejunum. Case report and review of the literature. Ital J Gastroenterol Hepatol (1997) 1.42
Amphipols: polymeric surfactants for membrane biology research. Cell Mol Life Sci (2003) 1.42
Current practice of brain death determination and use of confirmatory tests in an Italian University hospital: a report of 66 cases. Minerva Anestesiol (2013) 1.41
Detection of suspected primary lung cancer by scintigraphy with indium-111-anti-carcinoembryonic antigen monoclonal antibodies (type F023C5) J Nucl Med (1991) 1.41
Endocrine pancreatic tumors: factors correlated with survival. Ann Oncol (2005) 1.41
Longins: a new evolutionary conserved VAMP family sharing a novel SNARE domain. Trends Biochem Sci (2001) 1.41
miR-29b sensitizes multiple myeloma cells to bortezomib-induced apoptosis through the activation of a feedback loop with the transcription factor Sp1. Cell Death Dis (2012) 1.40
Changed epidemiology of ICU acquired bloodstream infections over 12 years in an Italian teaching hospital. Minerva Anestesiol (2014) 1.40
Leiomyomatosis in pelvic lymph nodes. Histopathology (1992) 1.39
High prevalence of retinoblastoma protein loss in triple-negative breast cancers and its association with a good prognosis in patients treated with adjuvant chemotherapy. Ann Oncol (2009) 1.34
Cervical vagal schwannoma. A case report. Acta Otorhinolaryngol Ital (2009) 1.33
cAMP-dependent protein kinase: role in normal and malignant growth. Crit Rev Oncol Hematol (1995) 1.33
Indomethacin-induced prostaglandin inhibition with hyperkalemia. A reversible cause of hyporeninemic hypoaldosteronism. Ann Intern Med (1979) 1.30
Relationship between techniques taught and practice behavior: education and clinical correlation. J Manipulative Physiol Ther (1999) 1.28
Dependence of the shape of the plasma fibronectin molecule on solvent composition. Ionic strength and glycerol content. J Biol Chem (1983) 1.28
Role of FK506-binding protein 51 in the control of apoptosis of irradiated melanoma cells. Cell Death Differ (2010) 1.26
The role of eukaryotic initiation factor 5A in the control of cell proliferation and apoptosis. Amino Acids (2001) 1.26
Concomitant CXCR4 and CXCR7 expression predicts poor prognosis in renal cancer. Curr Cancer Drug Targets (2010) 1.25
The natural history of untreated hyperprolactinemia: a prospective analysis. J Clin Endocrinol Metab (1989) 1.25
Physiology and biochemistry of endothelial function in children with chronic renal failure. Kidney Int (1997) 1.24
Polypeptide hormone regulation of gene expression. Thyrotropin-releasing hormone rapidly stimulates both transcription of the prolactin gene and the phosphorylation of a specific nuclear protein. J Biol Chem (1983) 1.24
Nicotine gum, 2 and 4 mg, for nicotine dependence. A double-blind placebo-controlled trial within a behavior modification support program. Chest (1995) 1.22
BAG3 protein regulates stress-induced apoptosis in normal and neoplastic leukocytes. Leukemia (2004) 1.22
Zoledronic acid induces antiproliferative and apoptotic effects in human pancreatic cancer cells in vitro. Br J Cancer (2003) 1.21
Multiple-target drugs: inhibitors of heat shock protein 90 and of histone deacetylase. Curr Drug Targets (2005) 1.21
Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFIRI chemotherapy. Pharmacogenomics J (2007) 1.20
Inhibition of the SH3 domain-mediated binding of Src to the androgen receptor and its effect on tumor growth. Oncogene (2007) 1.20
Dyskerin expression influences the level of ribosomal RNA pseudo-uridylation and telomerase RNA component in human breast cancer. J Pathol (2006) 1.20
The intestinal ecosystem in chronic functional constipation. Acta Paediatr (1998) 1.18
Necropsy studies in myocardial infarction with minimal or no coronary luminal reduction due to atherosclerosis. Circulation (1974) 1.18
Gemcitabine/cannabinoid combination triggers autophagy in pancreatic cancer cells through a ROS-mediated mechanism. Cell Death Dis (2011) 1.18
PATZ1 gene has a critical role in the spermatogenesis and testicular tumours. J Pathol (2008) 1.17
Metabotropic glutamate 1alpha and adenosine A1 receptors assemble into functionally interacting complexes. J Biol Chem (2001) 1.17
The role of Aurora-A inhibitors in cancer therapy. Ann Oncol (2007) 1.16
Cetuximab and irinotecan as third-line therapy in advanced colorectal cancer patients: a single centre phase II trial. Br J Cancer (2006) 1.14
Guidelines for the diagnosis and treatment of hyperprolactinemia. J Reprod Med (1999) 1.13
Accelerated bone mass senescence after hematopoietic stem cell transplantation. Transl Med UniSa (2013) 1.13
Interferon-alpha induces apoptosis in human KB cells through a stress-dependent mitogen activated protein kinase pathway that is antagonized by epidermal growth factor. Cell Death Differ (1999) 1.13
Dieulafoy's disease associated with early gastric cancer. J Clin Pathol (1995) 1.13
Formation of a Sindbis virus nonstructural protein and its relation of 42S mRNA function. J Virol (1976) 1.13
Debrancher deficiency: neuromuscular disorder in 5 adults. Ann Neurol (1979) 1.12
The structural origin of nonplanar heme distortions in tetraheme ferricytochromes c3. Biochemistry (1998) 1.12
Induction of neutralizing antibodies and cytotoxic T lymphocytes in Balb/c mice immunized with virus-like particles presenting a gp120 molecule from a HIV-1 isolate of clade A. Antiviral Res (2002) 1.12
Morphology of acute myocardial infarction in relation to coronary thrombosis. Am Heart J (1974) 1.12
Diagnosis of midline anomalies of the fetal brain with the three-dimensional median view. Ultrasound Obstet Gynecol (2006) 1.11
Clone heterogeneity in diploid and aneuploid breast carcinomas as detected by FISH. Cytometry (2001) 1.11
Distribution of enteric neurons showing immunoreactivity for substance P in the guinea-pig ileum. Neuroscience (1980) 1.10
Frequent loss of expression of the cyclin-dependent kinase inhibitor p27 in epithelial ovarian cancer. Cancer Res (1999) 1.10
Antitumor therapeutic strategies based on the targeting of epidermal growth factor-induced survival pathways. Curr Drug Targets (2005) 1.10
Expression of A2B adenosine receptors in human lymphocytes: their role in T cell activation. J Cell Sci (1999) 1.10